JADE101 / Jade Biosciences - LARVOL DELTA

Interim Results of a Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JADE101 in Healthy Volunteers. (ERA 2026) - "Neutralization of APRIL by JADE101 in HVs is anticipated to translate similarly to patients with IgAN, leading to suppression of IgA and Gd-IgA1 production, reduction in proteinuria and stabilization of eGFR. The biomarker-rich and translationally predictive data from this FIH evaluation establish the foundation for subsequent clinical development of JADE101, a potentially disease modifying therapy in IgAN with convenient, infrequent SC dosing."

Clinical • First-in-human • P1 data • PK/PD data • Glomerulonephritis • IgA Nephropathy • Immunology • Nephrology • Renal Disease

A Phase 2, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of Jade101 in Participants with Immunoglobulin A Nephropathy (ERA 2026) - No abstract available

Clinical • P2 data • Glomerulonephritis • IgA Nephropathy • Renal Disease

A Study of JADE101 in Participants With Immunoglobulin A Nephropathy (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: Jade Biosciences, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Glomerulonephritis • IgA Nephropathy • Renal Disease

Jade Biosciences…announced that it will host a conference call and webcast on Monday, June 1, 2026, at 8:00 a.m. ET to discuss results from the ongoing Phase 1 healthy volunteer study of JADE101 (GlobeNewswire) - "The data are expected to define the dosing strategy and further characterize JADE101’s clinical profile as a potentially differentiated, disease-modifying anti–A Proliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobulin A nephropathy (IgAN)."

P1 data • IgA Nephropathy

Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy (GlobeNewswire) - "JUNIPER is an open-label Phase 2 clinical trial designed to evaluate JADE101 in approximately 30 participants with IgAN, including its safety and tolerability, changes in urine protein-to-creatinine ratio, a key prognostic marker of risk of disease progression, renal function as measured by estimated glomerular filtration rate, and resolution of hematuria....Interim Phase 2 JADE101 data are expected in 2027."

P2 data • Trial status • IgA Nephropathy

A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese Participants (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Jade Biosciences, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open

A Phase 2 Study of JADE101 in Participants With Immunoglobulin A Nephropathy (clinicaltrials.gov) - P2 | N=30 | Not yet recruiting | Sponsor: Jade Biosciences, Inc.

New P2 trial • Glomerulonephritis • IgA Nephropathy • Renal Disease

A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese Participants (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Jade Biosciences, Inc.

New P1 trial

A TRANSLATIONAL FRAMEWORK TO PREDICT CLINICAL RESPONSES TO APRIL BLOCKADE FOR DEVELOPMENT OF JADE101, AN ANTIAPRIL MONOCLONAL ANTIBODY IN IGAN (ISN-WCN 2026) - "Complete APRIL neutralization in HVs appears to ultimately predict deep IgA and Gd-IgA1 suppression and maximal proteinuria reductions in IgAN patients. These associations provide a foundation for JADE101 development, a potentially disease modifying therapy in IgAN with convenient, infrequent dosing."This abstract was also submitted for the ASN 2025.""

Clinical • IO biomarker • Glomerulonephritis • IgA Nephropathy • Immunology